<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Cabaletta Bio Inc — News on 6ix</title>
<link>https://6ix.com/company/cabaletta-bio-inc</link>
<description>Latest news and press releases for Cabaletta Bio Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/cabaletta-bio-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835518178dffbe2df0e7a5e.webp</url>
<title>Cabaletta Bio Inc</title>
<link>https://6ix.com/company/cabaletta-bio-inc</link>
</image>
<item>
<title>Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel</title>
<link>https://6ix.com/company/cabaletta-bio-inc/news/cellares-and-cabaletta-bio-sign-10-year-commercial-supply-agreement-to-scale-rese-cel</link>
<guid isPermaLink="true">https://6ix.com/company/cabaletta-bio-inc/news/cellares-and-cabaletta-bio-sign-10-year-commercial-supply-agreement-to-scale-rese-cel</guid>
<pubDate>Tue, 28 Apr 2026 12:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., April 28, 2026--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced it has entered into a 10-year commercial supply agreement with Cabaletta Bio Inc. (Nasdaq: CABA) for the automated manufacture of rese-cel (resecabtagene autoleucel), Cabaletta’s investigational CAR T cell therapy for autoimmune diseases. The agreement secures the long-term manufacturing capacity and supply predictability required to address the global pa</description>
</item>
<item>
<title>Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel</title>
<link>https://6ix.com/company/cabaletta-bio-inc/news/cabaletta-bio-and-cellares-announce-10-year-commercial-supply-agreement-for-rese-cel</link>
<guid isPermaLink="true">https://6ix.com/company/cabaletta-bio-inc/news/cabaletta-bio-and-cellares-announce-10-year-commercial-supply-agreement-for-rese-cel</guid>
<pubDate>Tue, 28 Apr 2026 12:00:00 GMT</pubDate>
<description>Agreement facilitates flexible, scalable automated industrialized production of rese-cel for many thousands of patients per year at a cost per batch that is among the lowest in the industry Initial translational data from the first two patients dosed with rese-cel manufactured by Cellares will be presented at the ASGCT conference in May PHILADELPHIA and SOUTH SAN FRANCISCO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company</description>
</item>
<item>
<title>Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting</title>
<link>https://6ix.com/company/cabaletta-bio-inc/news/cabaletta-bio-announces-multiple-upcoming-presentations-including-data-on-rese-cel-without-preconditioning-and-rese-cel-with-automated-manufacturing-at-the-asgct-2026-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/cabaletta-bio-inc/news/cabaletta-bio-announces-multiple-upcoming-presentations-including-data-on-rese-cel-without-preconditioning-and-rese-cel-with-automated-manufacturing-at-the-asgct-2026-annual-meeting</guid>
<pubDate>Mon, 27 Apr 2026 21:00:00 GMT</pubDate>
<description>PHILADELPHIA, April 27, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching targeted cell therapies designed specifically for patients with autoimmune diseases, today announced multiple upcoming presentations including manufacturing, translational and clinical data on rese-cel (resecabtagene autoleucel) at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting, being held from May 11-15, 202</description>
</item>
<item>
<title>First Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform</title>
<link>https://6ix.com/company/cabaletta-bio-inc/news/first-patients-dosed-with-cabaletta-bios-rese-cel-manufactured-on-cellares-automated-cell-shuttletm-platform</link>
<guid isPermaLink="true">https://6ix.com/company/cabaletta-bio-inc/news/first-patients-dosed-with-cabaletta-bios-rese-cel-manufactured-on-cellares-automated-cell-shuttletm-platform</guid>
<pubDate>Tue, 14 Apr 2026 04:00:00 GMT</pubDate>
<description>First two GMP doses of rese-cel manufactured on the Cell Shuttle™ met all release specifications, were delivered on time, and have been infused into patients</description>
</item>
<item>
<title>Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/cabaletta-bio-inc/news/cabaletta-bio-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/cabaletta-bio-inc/news/cabaletta-bio-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>Rese-cel myositis BLA submission on track for 2027 based on a 17-patient, single arm registrational cohort design, including an outpatient dosing option</description>
</item>
<item>
<title>Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference</title>
<link>https://6ix.com/company/cabaletta-bio-inc/news/cabaletta-bio-to-participate-in-the-td-cowen-46th-annual-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/cabaletta-bio-inc/news/cabaletta-bio-to-participate-in-the-td-cowen-46th-annual-health-care-conference</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>PHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and</description>
</item>
<item>
<title>Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026</title>
<link>https://6ix.com/company/cabaletta-bio-inc/news/cabaletta-bio-participate-guggenheim-emerging-130000912</link>
<guid isPermaLink="true">https://6ix.com/company/cabaletta-bio-inc/news/cabaletta-bio-participate-guggenheim-emerging-130000912</guid>
<pubDate>Thu, 05 Feb 2026 13:00:00 GMT</pubDate>
<description>PHILADELPHIA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 9:30 a.m. ET in New York, NY. A live webcast of the presentation will be</description>
</item>
<item>
<title>Cabaletta Bio Announces 2026 Strategic Priorities</title>
<link>https://6ix.com/company/cabaletta-bio-inc/news/cabaletta-bio-announces-2026-strategic-130000529</link>
<guid isPermaLink="true">https://6ix.com/company/cabaletta-bio-inc/news/cabaletta-bio-announces-2026-strategic-130000529</guid>
<pubDate>Mon, 12 Jan 2026 13:00:00 GMT</pubDate>
<description>Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission – including an outpatient dosing option using a single weight-based dose IND amendment cleared to manufacture rese-cel with the automated, scalable Cellares platform based on multiple successful engineering runs; clinical manufacturing data expected in 1H26 to confirm GMP readiness, including supply chain logistics New durability data without preconditioning and higher dose initial cl</description>
</item>
<item>
<title>IND Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel from Cabaletta Bio Using Cellares' Automated Platforms</title>
<link>https://6ix.com/company/cabaletta-bio-inc/news/ind-amendment-clearance-obtained-for-clinical-manufacturing-of-rese-cel-from-cabaletta-bio-using-cellares-automated-platforms</link>
<guid isPermaLink="true">https://6ix.com/company/cabaletta-bio-inc/news/ind-amendment-clearance-obtained-for-clinical-manufacturing-of-rese-cel-from-cabaletta-bio-using-cellares-automated-platforms</guid>
<pubDate>Mon, 12 Jan 2026 12:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., January 12, 2026--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Cabaletta Bio’s (Nasdaq: CABA) investigational CAR T cell therapy rese-cel (resecabtagene autoleucel) has received FDA clearance of an IND Amendment (INDa) to use Cellares’ Cell Shuttle™ and Cell Q™ platforms for manufacturing and QC release testing.</description>
</item>
<item>
<title>Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/cabaletta-bio-inc/news/cabaletta-bio-reports-third-quarter-123000609</link>
<guid isPermaLink="true">https://6ix.com/company/cabaletta-bio-inc/news/cabaletta-bio-reports-third-quarter-123000609</guid>
<pubDate>Mon, 10 Nov 2025 12:30:00 GMT</pubDate>
<description>Rese-cel data presented at multiple medical meetings demonstrated potentially transformative, drug-free clinical responses with a favorable safety profile for autoimmune patients supporting outpatient use All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who would have met key criteria for the registrational cohort met the registrational, 16-week primary endpoint Planned BLA submission for rese-cel in 2027 based on 14-patient, single-arm DM/ASyS registrational cohor</description>
</item>
<item>
<title>Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December</title>
<link>https://6ix.com/company/cabaletta-bio-inc/news/cabaletta-bio-participate-upcoming-investor-130000737</link>
<guid isPermaLink="true">https://6ix.com/company/cabaletta-bio-inc/news/cabaletta-bio-participate-upcoming-investor-130000737</guid>
<pubDate>Tue, 04 Nov 2025 13:00:00 GMT</pubDate>
<description>PHILADELPHIA, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in the following upcoming investor conferences in November and December: Guggenheim’s 2nd Annual Healthcare Innovation Conference: Webcasted fireside chat at 10:30 a.m. ET on Tuesday, Nov</description>
</item>
<item>
<title>Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025</title>
<link>https://6ix.com/company/cabaletta-bio-inc/news/cabaletta-bio-presents-positive-clinical-110000217</link>
<guid isPermaLink="true">https://6ix.com/company/cabaletta-bio-inc/news/cabaletta-bio-presents-positive-clinical-110000217</guid>
<pubDate>Mon, 27 Oct 2025 11:00:00 GMT</pubDate>
<description>– All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria exceeded the registrational primary endpoint, demonstrating major TIS responses with no immunomodulators – – Myositis registrational trial being initiated this quarter with a planned cohort of 14 DM/ASyS patients and a 16-week primary endpoint – moderate or major TIS while off immunomodulators and on no or low-dose steroids – consistent with FDA alignment on key trial p</description>
</item>
<item>
<title>Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant</title>
<link>https://6ix.com/company/cabaletta-bio-inc/news/cabaletta-bio-announces-appointment-steve-120000984</link>
<guid isPermaLink="true">https://6ix.com/company/cabaletta-bio-inc/news/cabaletta-bio-announces-appointment-steve-120000984</guid>
<pubDate>Tue, 14 Oct 2025 12:00:00 GMT</pubDate>
<description>– Gavel brings highly relevant CAR T experience from Legend Biotech where he led the launch and commercialization of CARVYKTI® from 2018 until 2025 – PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced the appointment of Steve Gavel as Chief Commercial Officer, effective i</description>
</item>
<item>
<title>Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress</title>
<link>https://6ix.com/company/cabaletta-bio-inc/news/cabaletta-bio-presents-first-rese-160000945</link>
<guid isPermaLink="true">https://6ix.com/company/cabaletta-bio-inc/news/cabaletta-bio-presents-first-rese-160000945</guid>
<pubDate>Thu, 09 Oct 2025 16:00:00 GMT</pubDate>
<description>– Complete B cell depletion, rapid reduction in autoantibodies and near-complete resolution of clinical symptoms in two of three refractory patients; all three patients remained off immunomodulators since infusion and are off or tapering steroids as of the data cut-off – – CAR T cell expansion in all three patients without preconditioning was similar to expansion across 30+ patients dosed with preconditioning in the other RESET™ trials – – Initial dose data support continued exploration of rese-</description>
</item>
<item>
<title>Cabaletta Bio to Participate in Upcoming Investor Conferences in September</title>
<link>https://6ix.com/company/cabaletta-bio-inc/news/cabaletta-bio-participate-upcoming-investor-120000739</link>
<guid isPermaLink="true">https://6ix.com/company/cabaletta-bio-inc/news/cabaletta-bio-participate-upcoming-investor-120000739</guid>
<pubDate>Wed, 27 Aug 2025 12:00:00 GMT</pubDate>
<description>PHILADELPHIA, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in the following upcoming investor conferences in September: Cantor Global Healthcare Conference 2025: Webcasted fireside chat at 10:55 a.m. ET on Wednesday, September 3, 2025, in New Yor</description>
</item>
<item>
<title>Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/cabaletta-bio-inc/news/cabaletta-bio-reports-second-quarter-113000979</link>
<guid isPermaLink="true">https://6ix.com/company/cabaletta-bio-inc/news/cabaletta-bio-reports-second-quarter-113000979</guid>
<pubDate>Thu, 07 Aug 2025 11:30:00 GMT</pubDate>
<description>– Registrational cohort enrollment in RESET-Myositis™ trial on track to start in 2H25 with anticipated 2027 BLA submission for rese-cel in myositis – – Five disease-specific cohorts fully enrolled in the RESET™ clinical development program from over 70 clinical sites as of July 31, 2025, with expansion phase enrollment continuing – – FDA meetings to align on the next wave of registrational cohorts for rese-cel anticipated in 3Q25 for lupus, 4Q25 for systemic sclerosis and 1H26 for myasthenia gra</description>
</item>
<item>
<title>Cabaletta Bio Announces Pricing of Public Offering of Securities</title>
<link>https://6ix.com/company/cabaletta-bio-inc/news/cabaletta-bio-announces-pricing-public-135400261</link>
<guid isPermaLink="true">https://6ix.com/company/cabaletta-bio-inc/news/cabaletta-bio-announces-pricing-public-135400261</guid>
<pubDate>Wed, 11 Jun 2025 13:54:00 GMT</pubDate>
<description>PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced today the pricing of an underwritten public offering consisting of (i) 39,200,000 shares of its common stock and accompanying warrants to purchase an aggregate of 39,200,000 shares of common stock</description>
</item>
<item>
<title>Cabaletta Bio Announces Proposed Public Offering of Securities</title>
<link>https://6ix.com/company/cabaletta-bio-inc/news/cabaletta-bio-announces-proposed-public-101500192</link>
<guid isPermaLink="true">https://6ix.com/company/cabaletta-bio-inc/news/cabaletta-bio-announces-proposed-public-101500192</guid>
<pubDate>Wed, 11 Jun 2025 10:15:00 GMT</pubDate>
<description>PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof) and, i</description>
</item>
<item>
<title>Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress</title>
<link>https://6ix.com/company/cabaletta-bio-inc/news/cabaletta-bio-announces-rese-cel-100000186</link>
<guid isPermaLink="true">https://6ix.com/company/cabaletta-bio-inc/news/cabaletta-bio-announces-rese-cel-100000186</guid>
<pubDate>Wed, 11 Jun 2025 10:00:00 GMT</pubDate>
<description>– 7 of 8 myositis patients achieved clinically meaningful TIS responses after discontinuation of all immunomodulators, while off or actively tapering steroids; responses were sustained throughout the follow-up period in all responding patients – – All SLE patients without nephropathy achieved definition of remission in SLE (DORIS) as of the latest follow-up, and all 7 SLE and LN patients experienced SLEDAI-2K reductions, while off all immunomodulators and steroids – – Both scleroderma patients d</description>
</item>
<item>
<title>Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference</title>
<link>https://6ix.com/company/cabaletta-bio-inc/news/cabaletta-bio-participate-jefferies-global-120000056</link>
<guid isPermaLink="true">https://6ix.com/company/cabaletta-bio-inc/news/cabaletta-bio-participate-jefferies-global-120000056</guid>
<pubDate>Thu, 29 May 2025 12:00:00 GMT</pubDate>
<description>PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 11:05 a.m. ET in New York, NY. A live webcast of the presentation will be available on the N</description>
</item>
</channel>
</rss>